The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pregnancy morbidity. However, the diagnosis of APS is not easy and is hampered by several problems including high prevalence of clinical symptoms and high variability between different assays resulting in a high false-positive rate. Currently APS can be diagnosed for example by detecting anti-β2-glycoprotein I antibodies by ELISA. It has been reported that β2-glycoprotein I (β2GPI) changes its conformation from a native to an active form and thereby it opens up enabling antibodies to bind a specific epitope. We amongst others have shown that epitope glycine40-arginine43 of domain I of β2GPI is predominantly responsible for binding thrombosis related antibodies. Antibodies with affinity towards other epitopes have not been associated with thrombosis. Despite these results the question remains whether these domain I antibodies are the only antibodies of importance for the detection of APS.
WilsonWAGharaviAEKoikeT. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum1999; 42: 1309–1311.
2.
LevineJSBranchDWRauchJ. The antiphospholipid syndrome. N Engl J Med2002; 346: 752–763.
3.
Bas de LaatHDerksenRHde GrootPG. Beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol2004; 112: 161–168.
4.
De GrootPGDerksenRHde LaatB. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost2008; 34: 347–355.
5.
De LaatBDerksenRHUrbanusRTde GrootPG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540–1545.
6.
IoannouYPericleousCGilesI. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280–290.
7.
IversonGMVictoriaEJMarquisDM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A1998; 95: 15542–15546.
8.
McNeeleyPADlottJSFurieRA. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost2001; 86: 590–595.
9.
De LaatBDerksenRHvan LummelMPenningsMTde GrootPG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood2006; 107: 1916–1924.
10.
KatoHEnjyojiK. Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: the presence of five Sushi domains. Biochemistry1991; 30: 11687–11694.
11.
De LaatBde GrootPGDerksenRH. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood2009; 114: 3656–3661.
12.
BoumaBde GrootPGvan den ElsenJM. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. Embo J1999; 18: 5166–5174.
13.
SteinkassererABarlowPNWillisAC. Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I. FEBS Lett1992; 313: 193–197.
14.
ShengYSaliAHerzogHLahnsteinJKrilisSA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol1996; 157: 3744–3751.
15.
SchwarzenbacherRZethKDiederichsK. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J1999; 18: 6228–6239.
16.
GalliMComfuriusPMaassenC. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990; 335: 1544–1547.
17.
MatsuuraEIgarashiYFujimotoMIchikawaKKoikeT. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177–178.
18.
McNeilHPSimpsonRJChestermanCNKrilisSA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A1990; 87: 4120–4124.
GalliMLucianiDBertoliniGBarbuiT. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood2003; 102: 2717–2723.
21.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
22.
HammelMKriechbaumMGriesA. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. J Mol Biol2002; 321: 85–97.
23.
AgarCvan OsGMMorgelinM. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood2010; 116: 1336–1343.
24.
De LaatBvan BerkelMUrbanusRT. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011; 63: 3960–3968.
25.
IversonGMReddelSVictoriaEJ. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol2002; 169: 7097–7103.
26.
IoannouYGilesILambrianidesA. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol2006; 6: 8–8.
27.
PozziNBanzatoABettinS. Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. Protein Sci2010; 19: 1065–1078.
28.
De LaatBPengoVPabingerI. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost2009; 7: 1767–1773.
29.
BanzatoAPozziNFrassonR. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res2011; 128: 583–586.
